The FDA granted fast-track approval based on these initial trial data in November 2015 and full approval in March 2017 for patients with metastatic EGFR T790M mutant positive NSCLC after progression on first or second generation anti-EGFR TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.